Iressa as Second Line Therapy in Advanced NSCLC-Asia
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, parallel group, phase III, multicenter, regional study. The
total number of patients expected to be exposed to study procedures is approximately 150
patients will be recruited by investigational sites throughout the Asia Pacific region that
have expertise in treating patients with NSCLC.